Rocket Pharmaceuticals Files 8-K

TL;DR

Rocket Pharma filed an 8-K, likely routine updates.

AI Summary

Rocket Pharmaceuticals, Inc. filed an 8-K on October 14, 2025, reporting other events and financial statements. The company, formerly known as Inotek Pharmaceuticals Corp, is incorporated in Delaware and headquartered in Cranbury, NJ.

Why It Matters

This filing indicates Rocket Pharmaceuticals is providing updates on its corporate activities and financial status to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• Rocket Pharmaceuticals, Inc. (company) — Registrant
• Inotek Pharmaceuticals Corp (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• October 14, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma

Filing Documents

• ef20057000_8k.htm (8-K) — 30KB
• ef20057000_ex99-1.htm (EX-99.1) — 18KB
• image00001.jpg (GRAPHIC) — 3KB
• 0001140361-25-038030.txt ( ) — 184KB
• rckt-20251014.xsd (EX-101.SCH) — 4KB
• rckt-20251014_lab.xml (EX-101.LAB) — 21KB
• rckt-20251014_pre.xml (EX-101.PRE) — 16KB
• ef20057000_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. On October 14, 2025, Rocket Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") has accepted resubmission of the Biologics License Application (BLA) for KRESLADI (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), a rare genetic immune disorder that predisposes patients to recurrent and fatal infections and is near-uniformly fatal in childhood without an allogeneic hematopoietic stem cell transplant. The PDUFA date set by the FDA is March 28, 2026. The Company is eligible for a Rare Pediatric Disease Priority Review Voucher (PRV), should KRESLADI be approved. A copy of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this report by reference.

Forward-Looking Statements

Forward-Looking Statements Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as "believes," "intends," "expects," "plans" and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that KRESLADI will be approved by the FDA or that the Company will receive a PRV. Reference is also made to other factors detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated October 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: October 14, 2025 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP

View Full Filing

View this 8-K filing on SEC EDGAR